MedTrace Logo

Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder

NCT01633853 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2016-02-15

Study results available
· View outcomes & findings →

Summary

It is hypothesised that the efficacy and safety of Vitamin D2 soft capsule to treat the Chronic Kidney Disease Mineral and Bone Disease (CKD-MBD) are equal to 1,25(OH)2 Vitamin D3 (Rocaltrol) in the patients with CKD stage 3-5.

Conditions

  • Vitamin D Deficiency

Interventions

DRUG

Vitamin D2

Treatment with Vit D2.

DRUG

1,25(OH)2 Vit D3

Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).

Sponsors & Collaborators

  • Beijing Municipal Science & Technology Commission

    collaborator OTHER

  • Dongliang Zhang, MD

    lead OTHER

Principal Investigators

  • Dongliang Zhang, Doctor · Nephrology Department of Beijing Friendship Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01633853 on ClinicalTrials.gov